<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606710</url>
  </required_header>
  <id_info>
    <org_study_id>Cogent-4 0806</org_study_id>
    <nct_id>NCT00606710</nct_id>
  </id_info>
  <brief_title>Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following</brief_title>
  <acronym>Cogent-4</acronym>
  <official_title>Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guidant Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guidant Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COGENT-4 Field Following Study will evaluate the clinical performance of the Boston
      Scientific TELIGEN 100 HE Implantable Cardioverter Defibrillator (ICD), the COGNIS 100 HE
      Cardiac Resynchronization Therapy ICD (CRT-D) systems and the RELIANCE 4-SITE defibrillation
      lead (when available). An optional sub-study will also evaluate the clinical performance of
      the Reverse Mode Switch (RMS) feature in the TELIGEN 100 HE DR ICD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Appropriate detection of ventricular arrhythmias</measure>
    <time_frame>Predischarge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appropriate shock conversion</measure>
    <time_frame>Predischarge</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Ventricular Tachycardia, Ventricular Fibrillation</condition>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cognis 100-D, Teligen DR, VR 100 HE</intervention_name>
    <description>ICD or CRT - Therapy</description>
    <other_name>Reliance Quadripolar Defibrillation Lead</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with risk of developing life threatening ventricular arrhythmias with and without
        heart failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICD indication according to normal clinical practice (for those patients receiving a
             TELIGEN 100 HE)

          -  CRT-D indication according to normal clinical practice (for those patients receiving a
             COGNIS 100 HE)

          -  Willing and capable of providing informed consent, undergoing a device implant,
             participating in all testing associated with this clinical investigation at an
             approved clinical investigational centre and at the intervals defined by this protocol

          -  Geographically stable patients who are available for follow-up at a study centre

          -  Age 18 or above, or of legal age to give informed consent specific to national law

        Exclusion Criteria:

          -  Documented life expectancy of less than six months or expected to undergo heart
             transplant within the next six months

          -  Patients currently requiring dialysis

          -  Women who are pregnant or plan to become pregnant. Method of assessment per physician
             discretion

          -  Enrolled in any concurrent study

          -  Patients implanted with the following leads which will not be abandoned:

          -  Atrial or right ventricular unipolar leads

          -  Patch defibrillation leads

          -  Non-compatible defibrillation leads (e.g. 5/6mm)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poul Erik Bloch Thomsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KAS Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KAS Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilay Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78306</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2008</study_first_posted>
  <last_update_submitted>November 21, 2008</last_update_submitted>
  <last_update_submitted_qc>November 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Torsten Kayser</name_title>
    <organization>Boston Scientific</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

